Corentec Co Ltd (104540) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Corentec Co Ltd KRW 10,770, price KRW 4,000, upside +169.3%, quality 66 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Corentec Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Corentec Co., Ltd., develops and sells orthopedic artificial joints in South Korea. Its orthopedic products include hip systems, such as Bencox ID stems, Bencox stems, Bencox modular revision stems, Bencox m stems, and Benfix long stems; and Bencox cups, Bencox bipolar cups, Bencox mirabo cups, and Bencox mirabo multi-hole cups.
Show more
Corentec Co., Ltd., develops and sells orthopedic artificial joints in South Korea. Its orthopedic products include hip systems, such as Bencox ID stems, Bencox stems, Bencox modular revision stems, Bencox m stems, and Benfix long stems; and Bencox cups, Bencox bipolar cups, Bencox mirabo cups, and Bencox mirabo multi-hole cups. The company also offers Lospa and Exult knee systems; spine systems, such as Lospa IS systems; Coralis shoulder systems; and trauma systems, including LCfit HTO plate systems and Optirad volar plate system. Corentec Co., Ltd. was founded in 2000 and is headquartered in Cheonan-si, South Korea.
Stock analysis
Corentec Co Ltd (104540) currently trades at 4,000 KRW, while our model-based Fair Value estimate is 10,770 KRW, implying the stock looks roughly 62.9% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 24,955 KRW per share, and 24 of the 24 models we run sit above the 4,000 KRW price.
Bear case: the Asset-Based group reads lowest at 4,106 KRW, and 0 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: 8,078 KRW (bear) to 13,463 KRW (bull), the price of 4,000 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Corentec Co Ltd reported revenue of 100B KRW in FY2025 versus 44.6B KRW in FY2021, a compound +22.5%/yr. Reported net income was 6.3B KRW in FY2025, compounding +69.2%/yr from FY2021.
Key figures
Market cap 51.1B KRW (≈ $37.6M) · P/S ratio 0.50 · Dividend yield 0.8% · Net margin 6.2% · Return on equity 4.2% · Return on assets (EBIT) 3.4% · Operating margin 3.6% · Revenue (TTM) 102B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 44% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 169%, 104540 screens cheaper than that median.
Fair Value models
Bear 8,078 KRWFair Value 10,770 KRWBull 13,463 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+7.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.9%
Start year 2020 (pandemic). Over 10 years: +12.7% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+42.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+41.3%
Dividend (yield on the price)0.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.29% vs 26%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 9%
2025 sits 112% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−28.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −29.5% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 7/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score66 · Top 25%
Fair Value upside+169% · Top 25%
Profitability
Return on equity (TTM)4% · Above median
Return on assets3% · Above median
Net margin (TTM)5% · Below median
Operating margin (TTM)4% · Below median
Growth and dividend
Revenue growth9% · Above median
Dividend yield (TTM)0.8% · Bottom 25%
Balance sheet
Debt / equity0.06× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Corentec Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/104540
Frequently asked questions
Is Corentec Co Ltd (104540) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 10,770 KRW versus a price of 4,000 KRW, about +169% upside (undervalued).
What is the fair value of 104540?
Our model-based fair value for Corentec Co Ltd is 10,770 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 4,000 KRW.
What is the quality score of 104540?
Corentec Co Ltd has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Corentec Co Ltd (104540)?
Our model-based price target is the fair value of 10,770 KRW (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 8,078 KRW, optimistic scenario 13,463 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Corentec Co Ltd stock forecast for 2026?
Our models put fair value at 10,770 KRW, about +169% upside versus a price of 4,000 KRW (undervalued). Cautious scenario 8,078 KRW, optimistic scenario 13,463 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Corentec Co Ltd (104540)?
Corentec Co Ltd reported trailing-twelve-month revenue of about 102B KRW (latest available figure, as of Sep 24, 2026).
Does Corentec Co Ltd pay a dividend?
Corentec Co Ltd currently shows a dividend yield of about 0.85% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Corentec Co Ltd (104540)?
For today's price to be fair in a discounted-cash-flow model, Corentec Co Ltd would have to grow free cash flow by -28.0 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +19.9 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 104540 use?
Our models discount Corentec Co Ltd at 8.9 %: a base by market capitalisation (nano), damped by beta 0.26, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Corentec Co Ltd that is -28.0 % per year a year over ten years, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has Corentec Co Ltd (104540) delivered so far?
Over the past 5 years revenue at Corentec Co Ltd grew +19.9 % a year. The price currently implies -28.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Corentec Co Ltd (104540) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Corentec Co Ltd (-28.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Corentec Co Ltd (104540)?
The free-cash-flow yield on the price is 44.70 %: that much free cash flow Corentec Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Corentec Co Ltd (104540)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Corentec Co Ltd it is 10,770 KRW per share (as of Sep 24, 2026), against a price of 4,000 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Corentec Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 104540 trades below its calculated fair value: price 4,000 KRW, fair value 10,770 KRW, a gap of about +169% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 104540?
No. The price is what the market pays today (4,000 KRW); the fair value is what the company's own numbers justify (10,770 KRW). For Corentec Co Ltd the two are 6,770 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Corentec Co Ltd worth?
The market values Corentec Co Ltd at about 51.1B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 4,000 KRW; our models calculate a fair value of 10,770 KRW per share.
What do the bullish and bearish scenarios say about 104540?
Our models span a range for Corentec Co Ltd: cautious scenario 8,078 KRW, base 10,770 KRW, optimistic 13,463 KRW per share (as of Sep 24, 2026, price 4,000 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Corentec Co Ltd (104540)?
Balance-sheet figures for Corentec Co Ltd (as of Sep 24, 2026): return on equity 4.2%, debt of 0.06 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is 104540 from its 52-week high?
Corentec Co Ltd trades at 4,000 KRW, about 44% below its 52-week high of 7,160 KRW and 8% above the low of 3,720 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 10,770 KRW is for.
Which stocks are comparable to Corentec Co Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Corentec Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 4,000 KRW, calculated fair value 10,770 KRW (+169%), Quality Score 66/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 104540 calculated?
We run Corentec Co Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 10,770 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Corentec Co Ltd currently trades 169 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Corentec Co Ltd (104540)?
The closing price on Sep 23, 2026 was 4,000 KRW. Our model-based fair value is 10,770 KRW, about +169% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Corentec Co Ltd right now?
The price is below even our cautious bear case (8,078 KRW). The market is more pessimistic than our downside scenario. Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Corentec Co Ltd
How large is the market capitalisation of Corentec Co Ltd (104540)?
The market capitalisation of Corentec Co Ltd is 51.1B KRW (≈ $37.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Corentec Co Ltd (104540)?
The price-to-sales ratio of Corentec Co Ltd is 0.50 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Corentec Co Ltd (104540)?
The dividend yield of Corentec Co Ltd is 0.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Corentec Co Ltd (104540)?
The net margin of Corentec Co Ltd is 6.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Corentec Co Ltd (104540)?
The return on equity (ROE) of Corentec Co Ltd is 4.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Corentec Co Ltd (104540)?
On an EBIT basis the return on assets of Corentec Co Ltd is 3.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Corentec Co Ltd (104540)?
The operating margin of Corentec Co Ltd is 3.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Corentec Co Ltd (104540)?
Revenue at Corentec Co Ltd is growing +8.6% versus a year earlier (3y avg +16.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Corentec Co Ltd (104540)?
Earnings per share at Corentec Co Ltd are growing −56.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Corentec Co Ltd (104540) carry?
The net debt of Corentec Co Ltd is 11.1B KRW (fiscal year 2025, ≈ 0.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Corentec Co Ltd in the live analysis
One click puts Corentec Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
